Related Experiment Video
Updated: Apr 14, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling
Hyung-Mun Yun1, Kyung-Ran Park1, Eun-Cheol Kim1
1Department of Maxillofacial Tissue Regeneration, School of Dentistry and Research Center for Tooth & Periodontal Regeneration (MRC), Kyung Hee University, Seoul 130-701, Republic of Korea.
Abstract:
Inflammation is associated with cancer-prone microenvironment, leading to cancer. IL-32 is expressed in chronic inflammation-linked human cancers. To investigate IL-32α in inflammation-linked colorectal carcinogenesis, we generated a strain of mice, expressing IL-32 (IL-32α-Tg). In IL-32α-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-mediated apoptosis was increased. Also, IL-32α increased ROS production to induce prolonged JNK activation. In colon cancer patients, IL-32α and TNFR1 were increased. These findings indicate that IL-32α suppressed colon cancer development by promoting the death signaling of TNFR1.
Insights
Interleukin-32 alpha (IL-32α) suppresses colon cancer by enhancing tumor cell death signaling. This finding suggests IL-32α could be a therapeutic target for inflammation-linked colorectal cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Inflammation creates a microenvironment conducive to cancer development.
- Interleukin-32 (IL-32) is implicated in human cancers associated with chronic inflammation.
Purpose of the Study:
- To investigate the role of Interleukin-32 alpha (IL-32α) in inflammation-driven colorectal carcinogenesis.
- To elucidate the mechanisms by which IL-32α influences colon cancer development.
Main Methods:
- Generation of a transgenic mouse model expressing IL-32α (IL-32α-Tg).
- Induction of colon cancer in mice using azoxymethane (AOM).
- Analysis of tumor incidence, TNFR1 expression, apoptosis, reactive oxygen species (ROS) production, and JNK activation.
Main Results:
- IL-32α transgenic mice exhibited decreased AOM-induced colon cancer incidence.
- Expression of TNFR1 and TNFR1-mediated apoptosis were increased in IL-32α-Tg mice.
- IL-32α elevated ROS production, leading to sustained JNK activation, and was found to be upregulated in human colon cancer patients alongside TNFR1.
Conclusions:
- IL-32α suppresses colon cancer development.
- This suppression is mediated by promoting TNFR1-dependent apoptosis signaling.
- IL-32α may represent a novel therapeutic target for colorectal cancer prevention and treatment.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
TGF - β Signaling Pathway
Tumor Immunotherapy
The Extrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

